CSE:AGN - Post Discussion
Post by
waves1 on Jul 21, 2022 2:41pm
AGN CEO discussing IPF & chronic cough study results
Algernon Pharmaceuticals ($AGN.c $AGNPF) CEO on Proactive discussing its study of IPF and chronic cough:
https://www.youtube.com/watch?v=zZbYVwEvnUU&ab_channel=Proactive
The data showed 65% of patients with stable or improved forced vital capacity over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%.
Achieving statistical significance with such a small study size is quite significant and is a good sign for the IPF phase 2b study going forward.
The entire report is expected to be released in August which could be a catalyst for the stock price as bringing a new IPF treatment that also reduced chronic cough to the market is a major development for the industry.
Be the first to comment on this post